Filter the latest scan's published facts — sector, size, yield, valuation — or rank them with a preset: cheapest, fastest growing, most profitable. Every view shows what is in the filings and prices; none ranks opportunity. The model behind the statuses showed no predictive power, and nothing here is a recommendation.
Scan of 2026-08-31 · 2,409 names scored · prices as of that date
Lowest valid-in-sector trailing valuation multiples today, latest scan: each name's sector percentiles on earnings yield, FCF yield, P/S, P/B, P/TBV and P/CFO, averaged (only the metrics valid in its sector — a REIT is never ranked by GAAP P/E here). “Cheapest” is a fact about trailing multiples versus sector peers, not a forecast that they re-rate.
Tested the unforgiving way: a composite ranking built from these same point-in-time filings (2017-01-31 to 2026-05-29) showed no measurable predictive power (mean IC 0.0168, t = 1.21), and its top quintile did not beat holding everything even before costs. Ranks like these describe today's record; they do not predict tomorrow's return.
284 names — page 6 of 6 · sector: Pharma & chemicals · Export CSV
| # | Ticker | Company | Sector | Cheap composite | P/E (trailing) | P/S (trailing) | FCF yield | Own 5y |
|---|---|---|---|---|---|---|---|---|
| 251 | PGEN | Precigen, Inc. Common Stock | Pharma & chemicals | 29.4 | — | 78.1× | -4.7% | +1.3σ |
Never the absolute multiple alone. A P/E of 9 is a fact; whether it is low depends on what you hold it against.
The five-year window is the empirically privileged one. Cheap against its sector and cheap against its own history are different claims, and a stock can be one without being the other — which is the whole reason both columns are shown rather than blended into a single score.
| 252 | RVMD | Revolution Medicines, Inc. Common Stock | Pharma & chemicals | 29.3 | — | — | -2.6% | +1.8σ |
| 253 | DBVT | DBV Technologies S.A. | Pharma & chemicals | 29.0 | — | — | -3.7% | +0.8σ |
| 254 | ALMS | Alumis Inc. Common Stock | Pharma & chemicals | 28.8 | — | 330× | -13.6% | — |
| 255 | NRIX | Nurix Therapeutics, Inc. Common stock | Pharma & chemicals | 28.7 | — | 37.1× | -10.2% | +0.8σ |
| 256 | MIRM | Mirum Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 28.4 | — | 10.5× | -2.9% | +0.7σ |
| 257 | ABSI | Absci Corporation Common Stock | Pharma & chemicals | 28.2 | — | — | -7.0% | +1.1σ |
| 258 | ZYME | Zymeworks Inc. | Pharma & chemicals | 28.2 | — | 26.5× | -3.6% | −0.3σ |
| 259 | RCUS | Arcus Biosciences, Inc. | Pharma & chemicals | 27.8 | — | 15.6× | -13.3% | −0.3σ |
| 260 | VKTX | Viking Therapeutics, Inc | Pharma & chemicals | 27.4 | — | — | -9.0% | −0.3σ |
| 261 | IONS | Ionis Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 26.7 | — | 9.5× | -9.7% | −1.4σ |
| 262 | LQDA | Liquidia Corporation Common Stock | Pharma & chemicals | 26.0 | 270× | 20.9× | 0.7% | +1.2σ |
| 263 | NVCT | Nuvectis Pharma, Inc. Common Stock | Pharma & chemicals | 26.0 | — | — | -3.0% | +1.7σ |
| 264 | TSHA | Taysha Gene Therapies, Inc. Common Stock | Pharma & chemicals | 25.8 | — | 219× | -6.9% | +0.7σ |
| 265 | RYTM | Rhythm Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 25.6 | — | 33.4× | -1.7% | +0.6σ |
| 266 | PRLD | Prelude Therapeutics Incorporated | Pharma & chemicals | 25.6 | — | 21.1× | -12.4% | +0.8σ |
| 267 | SRRK | Scholar Rock Holding Corporation Common Stock | Pharma & chemicals | 25.2 | — | — | -4.5% | +0.9σ |
| 268 | AVTX | Avalo Therapeutics, Inc. Common Stock | Pharma & chemicals | 24.0 | — | — | -12.5% | +0.7σ |
| 269 | SMMT | Summit Therapeutics Inc. Common Stock | Pharma & chemicals | 23.6 | — | — | -3.6% | +0.5σ |
| 270 | INSM | Insmed, Inc. | Pharma & chemicals | 23.5 | — | 32.2× | -3.5% | +1.1σ |
| 271 | ZBIO | Zenas BioPharma, Inc. Common Stock | Pharma & chemicals | 22.7 | — | 202×FY | -10.4% | — |
| 272 | ATAI | AtaiBeckley Inc. Common Stock | Pharma & chemicals | 22.4 | — | — | -4.0% | — |
| 273 | KOD | Kodiak Sciences Inc Common Stock | Pharma & chemicals | 21.8 | — | — | -6.4% | +0.9σ |
| 274 | KURA | Kura Oncology, Inc. | Pharma & chemicals | 21.5 | — | 15.7× | -7.5% | −0.2σ |
| 275 | SPRY | ARS Pharmaceuticals, Inc. Common Stock | Pharma & chemicals | 20.0 | — | 6.0× | -29.4% | −0.8σ |
| 276 | REPL | Replimune Group, Inc. | Pharma & chemicals | 19.5 | — | — | -22.5%FY | +0.0σ |
| 277 | GLSI | Greenwich LifeSciences, Inc. | Pharma & chemicals | 19.1 | — | — | -5.8% | −1.2σ |
| 278 | QURE | uniQure N.V. | Pharma & chemicals | 18.7 | — | 191×FY | -5.6% | +0.4σ |
| 279 | VSTM | Verastem, Inc. | Pharma & chemicals | 18.7 | — | 20.5×FY* | -23.8% | +0.5σ |
| 280 | SNDX | Syndax Pharmaceuticals, Inc. | Pharma & chemicals | 17.3 | — | 7.9× | -16.3% | −0.6σ |
| 281 | RGNX | REGENXBIO Inc. | Pharma & chemicals | 14.3 | — | 5.6× | -48.2% | −1.3σ |
| 282 | ACHV | Achieve Life Sciences, Inc. | Pharma & chemicals | 14.2 | — | — | -10.7% | +0.9σ |
| 283 | PCT | PureCycle Technologies, Inc. Common stock | Pharma & chemicals | 14.0 | — | 108× | -14.9% | +0.2σ |
| 284 | BHVN | Biohaven Ltd. | Pharma & chemicals | 10.2 | — | — | -25.9% | +0.0σ |
"Cheap composite" is a 0–100 position among valid sector peers — the mean of the component metrics' sector percentiles. "—" means the scan published no figure, deliberately. "n/a — masked" means the metric is misleading in that name's sector (a REIT's GAAP P/E, a bank's FCF yield) — hover for the reason, which comes from the same sector-validity rules the composite itself respects. An FY tag marks a trailing-year figure built from an annual filing; hover for what that means.